Milestone Pharmaceuticals Inc expected to post a loss of 19 cents a share - Earnings Preview

Milestone Pharmaceuticals

10/08/2026 15:15

Milestone Pharmaceuticals Inc MIST.OQ MIST.O is expected to  show a rise in quarterly revenue when it reports  results on August 12 for the period ending June 30 2026
The Montreal Quebec-based  company is expected to report revenue of $816.67 thousand, according to the mean estimate from 6 analysts, based on LSEG data.
​LSEG's mean analyst estimate for Milestone Pharmaceuticals Inc is for a loss of 19 cents per share. 
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."  
The mean earnings estimate of analysts was unchanged in the last three months. ​
Wall Street's median 12-month price target for Milestone Pharmaceuticals Inc is $7.00, about 473.8% above its last closing price of $1.22
Previous quarterly performance (using preferred earnings measure in US dollars). ​
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE 
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2026
0.29
0.31
-0.20
Missed
-165.2
Dec. 31 2026
-0.16
-0.16
-0.18
Missed
-12.5
Sep. 30 2025
-0.15
-0.16
-0.12
Beat
26.8​
Jun. 30 2025
-0.20
-0.18
-0.20
Missed
-12.7
​​Mar. 31 2025
-0.17
-0.18
-0.31
Missed
-67.6
Dec. 31 2024
-0.14
-0.15
-0.20
Missed
-30.5​
Sep. 30 2024
-0.18
-0.16
-0.14
Beat
14.3
Jun. 30 2024
-0.19
-0.19
-0.14
Beat
26.3
This summary was machine generated August 10 at 14:15 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)